#Vienna #Austria #CGM #SIBIONICS #EASD

SiBionics' CGM + CKM Solutions at EASD 2025

At the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Vienna, SiBionics introduced its remarkable integrated solution for diabetes management, comprising Continuous Glucose Monitoring (CGM) and Continuous Ketone Monitoring (CKM) systems. This event garnered exceptional recognition from diabetes researchers and healthcare professionals around the globe due to its innovative technology aimed at improving patient outcomes.

The symposium titled "CGM + CKM for Better Diabetes Care" attracted experts from various fields who exchanged the latest scientific insights and the transformative potential of SiBionics' offerings. This exchange of knowledge sparked engaging discussions that underscored the effectiveness of SiBionics' approach in enhancing diabetes care.

The conference was co-chaired by distinguished figures including Professor Li-nung Chi from Peking University’s People’s Hospital and Professor Stefano Genovese from Italy. They were joined by other leading experts like Professor Andrej Janež from Slovenia, Professor Nina Jendrike from Germany, and Dr. I-fei Mo from China, who presented groundbreaking research findings regarding diabetes management.

Among the highlights was the SiBionics booth, where the next-generation devices, the GS3 CGM system and the KS3 CKM device, attracted significant attention from attendees. Visitors expressed considerable interest in the technological advantages and clinical applicability of these products, leading to active discussions with SiBionics representatives about their practical benefits in real-world diabetes treatment scenarios.

Crucially, a feasibility study revealed that SiBionics' system not only meets but exceeds the standards for integrated continuous glucose monitoring (iCGM) across several key performance indicators. The GS3 system is particularly noted for its exceptional accuracy and clinical reliability, particularly in hypoglycemic ranges, surpassing the requirements established for iCGM. This enhancement is vital for facilitating clinical decision-making and empowering patients in self-management of their condition.

SiBionics stands out as a burgeoning leader in the continuous monitoring sector, currently being the only company globally commercializing CKM technology. The firm has demonstrated remarkable capabilities in research and development, underpinned by a strong vision for innovation. Looking ahead, SiBionics plans to expand its Continuous Monitoring solutions, fostering innovations that deliver precise and high-quality care aimed at improving treatment outcomes for diabetes patients worldwide.

About SiBionics

Founded in 2015, SiBionics is a leading medical device manufacturer headquartered in Shenzhen and Irvine. Specializing in biosensor innovations, the company integrates continuous monitoring technology, intelligent algorithms, and user-friendly software to enhance health management. With over 500 employees, of whom 25% are dedicated to research and development, SiBionics is committed to advancing data-driven, personalized care.

For more information, you can visit their official website or reach out via email at [email protected]